0.00Open0.03Pre Close0 Volume669 Open Interest103.00Strike Price0.00Turnover143.43%IV-3.23%PremiumDec 6, 2024Expiry Date3.25Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3163Delta2.4267Gamma3325.00Leverage Ratio-74.1250Theta0.0000Rho-1051.66Eff Leverage0.0004Vega
Merck & Co Stock Discussion
On oct 10/24, open 2 x mrk contracts at 109.29c, strike at 105 and premium of 192 x 2 (35 dte). On nov 5/24, i closed 2 x contracts a...
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Positive
100% complete response rate achieved at 1.75 mg/kg dose level
High overall response rate across all dosage groups (93.3-100%)
Strong 12-month duration of response at 93.5%
Successfully established recommended Phase 3 dose
Negative
58% of patients exp...
No comment yet